Ingredient deep-dive

Motherwort: The One Trial Behind The Label

Search engine boxes fill with motherwort content about spiritual meaning, witchcraft and folk protection. Underneath all of that sits exactly one published human trial: fifty patients, twenty-eight days, a dose that can be stated precisely. Here is that trial in full, and what an in-vitro receptor study adds to explain it.

By GlucoPril Team · Last updated September 25, 2026 · 9 min read · Ingredient deep-dive

What motherwort is, and what it has been used for

Leonurus cardiaca is a tall, coarse perennial in the mint family, native to central Asia and long naturalised across Europe and North America. Its common name and its species name both point to the same traditional reputation: cardiaca for the heart, motherwort for childbirth and women’s complaints. Historically it has been used as a mild sedative, a remedy for heart palpitations that were not linked to structural disease, and for amenorrhea, dysmenorrhea and the anxiety that can accompany menopause.

A 2019 review updating the European Medicines Agency’s 2010 assessment of the herb summarises this traditional-use case and the research published since. It is a useful document precisely because it is candid about the gap: motherwort has centuries of traditional use and, at the time of that review, still very little modern trial evidence to stand alongside it.

This label names Motherwort Extract without specifying which part of the plant or how it was standardised. The traditional and research material is the aerial parts — the above-ground leaf, stem and flower — harvested at flowering, which is the presumed source here though the label does not say so.

Fifty patients, twenty-eight days

A search of the published, indexed literature for a randomised or controlled human trial of motherwort turns up one result. A 2011 study in Phytotherapy Research, run by a Russian and Saint-Petersburg-based team, opens by naming the problem directly: despite motherwort’s traditional reputation, clinical data on its effect in patients was lacking. The trial was designed to start filling that gap.

Fifty patients with stage 1 or stage 2 arterial hypertension, all with coexisting anxiety and sleep disturbance, were treated for 28 days with a Leonurus oil extract at 1200 mg a day. The design description in the indexed abstract does not state a placebo arm, so this is best read as an open clinical study of response over time rather than a blinded, placebo-controlled trial in the mould of the Cochrane hawthorn or hesperidin-chalcone reviews cited elsewhere on this site.

What it found: improvement in psycho-emotional status and blood pressure appeared about a week earlier in the stage 1 patients than the stage 2 patients. Using the Clinical Global Impression scale, a standard psychiatric rating tool, 32 per cent of patients showed significant improvement in anxiety and depression symptoms, 48 per cent showed moderate improvement, 8 per cent a weak effect, and 12 per cent did not respond. Side effects were minimal across all groups.

The left column is read off the seller's own ingredient graphic. The middle column is what the one published study used, not a prediction about this bottle.

Why it might do that: a receptor study

A single open clinical study is a starting point, not a mechanism, and it is worth knowing what laboratory work exists alongside it. A 2015 study tested standardised Leonurus cardiaca and the related Leonurus japonicus for their effect on rat GABAA receptors, the same receptor system that benzodiazepine anti-anxiety medicines act on.

The L. cardiaca extract inhibited binding at the GABA site with an IC50 of 21 micrograms per millilitre, a meaningfully high binding affinity in this kind of assay, while binding at the separate benzodiazepine site was 15 to 30 times weaker. That is a plausible pharmacological story for why a motherwort extract might calm an anxious patient: it appears to interact with the same neurotransmitter site as established anti-anxiety medicines, through a different part of the receptor than those medicines use.

A receptor-binding assay in isolated tissue is not proof that a swallowed dose reaches the brain at an active concentration, and the study’s authors are explicit that the compound responsible for the effect in L. cardiaca specifically remains unidentified — unlike its relative L. japonicus, where a known constituent explained the activity. What the assay does is make the 2011 clinical result less surprising than it would otherwise be.

Setting 1200 mg beside this bottle

Marketplace reports describe the actives in this formula grouped in a proprietary blend of about 121 mg, for all seven plants combined. The one human trial of motherwort used 1200 mg a day of that plant alone — nearly ten times the entire blend total, for one ingredient.

This is the widest gap of any ingredient covered on this site so far. Even granting motherwort the whole of the blend, which the ingredient list rules out by definition, the amount would fall roughly an order of magnitude short of the dose the only clinical study used.

How the research lines up with this label

The first column is read off the published research. The second is read off the seller’s artwork. The third is what a buyer is left holding.

What is on the safety record

The 2011 trial reported minimal side effects across all treatment groups, which is reassuring as far as it goes for a 28-day course at 1200 mg a day. It is one trial, and the traditional-use literature the EMA review summarises carries an older and more specific caution: motherwort’s traditional gynaecological uses — bringing on a delayed period, easing painful periods — describe an effect on the uterus, which is the standard reason herbal references advise against motherwort in pregnancy.

• The one clinical trial reported minimal side effects at 1200 mg a day for 28 days.
• Traditional use for delayed or painful periods points to uterine activity, which is why pregnancy is the standard caution for this plant.
• No drug-interaction study of motherwort was found in this search; anyone on a sedative, anti-anxiety or blood pressure medicine should raise it with a prescriber first.
• The label direction for this product covers all seven plants at once: for healthy adults, not for pregnancy or nursing.

What to make of it on this bottle

Motherwort is an honest case of a plant whose folklore vastly outpaces its clinical record. One open trial, fifty patients, a specific population and a specific extract, is what exists. It is a real, positive, and reasonably interesting result — not nothing, and also not the kind of ten-trial pooled evidence that this site’s article on the vein-and-capillary plants can point to for some of the other six names on this label.

None of that trial, and none of the receptor study that helps explain it, touches blood glucose. If this bottle is being taken for its front-of-pack claim, motherwort is not the ingredient doing the explaining, whatever the search engines suggest about its other reputations.

References